References
- Ronco C, Navalesi P, Vincent JL. Coronavirus epidemic: preparing for extracorporeal organ support in intensive care. Lancet Respir Med. 2020;8(3):240–241.
- Who.int. 2020. COVID-19 Public Health Emergency Of International Concern (PHEIC) Global Research And Innovation Forum. [online] Available at: <https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-pheic-global-research-and-innovation-forum> [Accessed2020Sept30].
- Worldometers.info. 2020. Coronavirus Update (Live): worldometer. [online] Available at: <https://www.worldometers.info/coronavirus/?> [Accessed2020Sept30].
- Clinicaltrials.gov. 2020. Home - Clinicaltrials.Gov. [online] Available at: <https://clinicaltrials.gov/ct2/home> [Accessed2020Sept30].
- Who.int. 2020. “Solidarity” Clinical Trial For COVID-19 Treatments. [online] Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments> [Accessed2020Sept30].
- *Esposito S, Noviello S, Pagliano P. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Le Infezioni Med. 2020Jun1;2:198–211.
- *Zumla A, Chan JF, Azhar EI, et al. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov. 2016May;15:(5):327–347.
- Cherian SS, Agrawal M, Basu A, et al. Perspectives for repurposing drugs for the coronavirus disease 2019. Indian J Med Res. 2020Feb1;151:(2):160.
- Lu R, Zhao X, Li J. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020Feb22; 395(10224):565–574.
- *Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan. Vol. 9. China: F1000Research; 2020.
- Glebov OO. Understanding the cell biology of SARS-CoV-2 endocytosis for COVID-19 drug repurposing: looking beyond chloroquine. FEBS J. 2020 May 19:10.1111/febs.
- Hoffmann M, Kleine-Weber H, Schroeder S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020Mar5;181:271–280.
- Senanayake SL. Drug repurposing strategies for COVID-19. Future Drug Discovery. 2020;2:6–8.
- Mims.com. 2020. Search Drug Information, Interactions, Images, Dosage & Side Effects | CIMS India. [online] Available at: <https://www.mims.com/india/> [Accessed2020Sept30].
- Noda A, Shirai T, Nakajima H. Case Report Two Cases of COVID-19 Pneumonia Including Use of Favipiravir. 2020;1–6. Available at:<http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200408_2.pdf> [Accessed 2020Aug21].
- **Cai Q, Yang M, Liu D. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020Mar18 [article in press]. https://doi.org/10.1016/j.eng.2020.03.00
- *Chen C, Huang J, Cheng Z. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020Jan1. [online] Available at: <https://doi.org/10.1101/2020.03.17.20037432>.
- **Yamamura H, Matsuura H, Nakagawa J, et al. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Crit Care. 2020Dec;24:(1):1–3.
- *Irie K, Nakagawa A, Fujita H. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID‐19. Clin Transl Sci. 2020May31;13:880–885.
- Gordon CJ, Tchesnokov EP, Woolner E. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020May15; 295(20):6785–6797.
- Eastman RT, Roth JS, Brimacombe KR. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Sci. 2020May;6(5):672–683.
- **Wang Y, Zhang D, Du G. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;6736:1–10.
- *Grein J, Ohmagari N, Shin D. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020 Jun 11; 382(24):2327–2336.
- Finberg RW, Dierberg K, Tapson V, et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. 2020;1–12.
- Gilead Sciences. Working to Supply Remdesivir for COVID-19. 2020;1–4. Available from: <https://www.gilead.com/purpose/advancing-global-health/covid-19/working-to-supply-remdesivir-for-covid-19> [Accessed2020Sept30].
- *Cao B, Wang Y, Wen D. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020Mar18;382:1787–1799.
- Cheng CY, Lee YL, Chen CP. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J Microbiol Immunol Infect. 2020Apr3;3 10.1016/j.jmii.2020.03.032
- *Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Jama. 2020May12;323:(18):1824–1836.
- COVID-19 Treatment Guidelines. 2020. Information On COVID-19 Treatment, Prevention And Research. [online] Available at: <https://www.covid19treatmentguidelines.nih.gov/> [Accessed2020Sept30].
- Arabi YM, Shalhoub S, Mandourah Y. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clinl Infect Dis. 2020Apr15; 70(9):1837–1844.
- Abreu GE, Aguilar ME, Covarrubias DH, et al. Amantadine as a drug to mitigate the effects of COVID-19. Med Hypotheses. 2020Apr;25:109755.
- *Wang Z, Yang B, Li Q, et al. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clinl Infect Dis. 2020Mar16;71(15):769–777.
- **Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis. 2003 Nov 1; 3:(11)722–727.
- Batra U, Sharma M, Redhu P. Chloroquine and hydroxychloroquine: clutching at straws in the time of COVID-19? Cancer Res Stat Treat. 2020Apr1; 3(5):3.
- Liu J, Cao R, Xu M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):1–4.
- *Savarino A, Di Trani L, Donatelli I, et al. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006Feb1; 6:(2)67–69.
- *Rome BN, Avorn J. Drug evaluation during the Covid-19 pandemic. N Engl J Med. 2020Apr14;10.1056/NEJMp2009457.
- *Geleris J, Sun Y, Platt J. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020May7;25 10.1056/NEJMoa2012410
- Chen Z, Hu J, Zhang Z. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020Jan [online]. Available at: <https://doi.org/10.1101/2020.03.22.20040758>.
- Tang W, Cao Z, Han M. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. medRxiv. 2020May7 [online]. Available at: <https://doi.org/10.1101/2020.04.10.20060558>
- Borba MG, Val FF, Sampaio VS. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Network Open. 2020Apr1; 3(4):e208857.
- Al‐Kofahi M, Jacobson P, Boulware DR. Finding the Dose for Hydroxychloroquine Prophylaxis for COVID‐19: the Desperate Search for Effectiveness. Clin Pharmacol Ther. 2020Apr28;108(4):766–769.
- Lentini G, Cavalluzzi MM, Habtemariam S. COVID-19, chloroquine repurposing, and cardiac safety concern: chirality might help. Molecules. 2020Jan; 25(8):1834.
- Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020Apr;3:104787.
- Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnol Biotechnol Equip. 2020Jan1;34(1):469–474.
- Padmanabhan S. Nitazoxanide – a potential ally in the treatment of COVID-19. 2020. Available at: <https://www.researchgate.net/profile/Srivatsan_Padmanabhan/publication/340902283_Nitazoxanide_-a_potential_ally_in_the_treatment_of_COVID-19/links/5ea333ef92851c1a906cfef2/Nitazoxanide-a-potential-ally-in-the-treatment-of-COVID-19.pdf> [Accessed 2020Aug21].
- Pindiprolu SK, Pindiprolu SH. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19. Med Hypotheses. 2020Apr; 22:109765.
- Abeygunasekera A, Jayasinghe S. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19? Med Hypotheses. 2020May; 18:109843.
- Baron SA, Devaux C, Colson P, et al. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19. Int J Antimicrob Agents. 2020Mar13;105944:10.1016.
- *Antinori S, Galimberti L, Milazzo L, et al. Bacterial and fungal infections among patients with SARS-CoV-2 pneumonia. hospitals. 2020Jun1;85:(77):90–96.
- Xu X, Han M, Li T. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Nat Acad Sci. 2020May19; 117(20):10970–10975.
- *Sallard E, Lescure FX, Yazdanpanah Y, et al. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020Apr;7:104791.
- Astrazeneca.com. Calquence Showed Promising Clinical Improvement In Majority Of 19 Hospitalised COVID-19 Patients. Available at: <https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-showed-promising-clinical-improvement-in-majority-of-19-hospitalised-covid-19-patients.html> [Accessed2020Sept30].
- Wang C, Li W, Drabek D. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020May4;11(1):1–6.
- Favalli EG, Biggioggero M, Maioli G, et al. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 3. 2020Apr3;20:1012–1013.
- Biocon Press Release. [online] Available at: <https://www.biocon.com/biocon_press_releases_2020.asp> [Accessed 2020Jul16].
- Sharma S, Ray A, Sadasivam B. Metformin in COVID-19 : A possible role beyond diabetes. Diabetes Res Clin Pract. 2020;164:108183.
- Jang S, Rhee JY. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy. Inter J Infect Dis. 2020May26;96:500–502.
- Sunpharma.com. 2020. Press Releases | sun Pharmaceutical Industries Ltd. [online] Available at: <https://www.sunpharma.com/media/press-releases> [Accessed 2020Jun10].
- *Monteil V, Kwon H, Prado P. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020Apr24;181(4):905–913.e7.
- *Abou-Ismail MY, Diamond A, Kapoor S, et al. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020Jun20;10.1016/j.thromres.2020.06.029
- Rogosnitzky M, Berkowitz E, Jadad AR. No Time to Waste: real-world Repurposing of Generic Drugs as a Multifaceted Strategy against COVID–19. JMIRx Med. 2020;1(1):e19583.
- *Ramcharan T, Nolan O, Lai CY. Paediatric Inflammatory Multisystem Syndrome: temporally Associated with SARS-CoV-2 (PIMS-TS): cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital. Pediatr Cardiol. 2020Jun;12:1.
- Lem FF, Opook F, Herng DL, et al. Molecular mechanism of action of repurposed drugs and traditional Chinese medicine used for the treatment of patients infected with COVID-19: A systematic review. medRxiv. 1. 2020Jan1 [online]. <https://doi.org/10.1101/2020.04.10.20060376>.
- Runfeng L, Yunlong H, Jicheng H. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020Mar; 20:104761.
- Ayush.gov.in. 2020. [online] Available at: <https://www.ayush.gov.in/docs/125.pdf> [Accessed 2020May17].
- Mohfw.gov.in. 2020. [online] Available at: <https://www.mohfw.gov.in/pdf/ImmunityBoostingAYUSHAdvisory.pdf> [Accessed2020May17].
- Hasan N, Nayem MU, Mohshinuzzaman M, et al. Homeopathic Approach to COVID-19: A Review. Malaysian J Med Bio Res. 2020Apr26; 7:(1)39–44.
- Jakovac H. COVID-19 and vitamin D—Is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab. 2020May1; 318(5):E589.
- Bleasel MD, Peterson GM. Emetine, ipecac, ipecac alkaloids and analogues as potential antiviral agents for coronaviruses. Pharmaceuticals. 2020Mar; 13(3):51.
- Manning TJ, Thomas-Richardson J, Cowan M, et al. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals. Drug Discov Today. 20. 2020Apr20;25(6):956–958.
- Delhi IIT, Science AI. Ashwagandha Takes The Lead To Be The Mother Nature’S COVID-19 Warrior: study. [online] Home.iitd.ac.in. Available at: <https://home.iitd.ac.in/news-covidaswagandha.php#.XsN2jkOwum8.linkedin> [Accessed2020Jun10].
- Rojas M, Rodríguez Y, Monsalve DM. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020May; 5(7):102554.
- *Shen C, Wang Z, Zhao F. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020Apr28; 323(16):1582–1589.
- Duan K, Liu B, Li C. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Nat Acad Sci. 2020Apr28; 117(17):9490–9496.
- Xinhuanet.com. 2020. China Puts 245 COVID-19 Patients On Convalescent Plasma Therapy - Xinhua | english.News.Cn. [online] Available at: <http://www.xinhuanet.com/english/2020-02/28/c_138828177.htm> [Accessed2020Jun7].
- Lenzer J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ. 2020Apr; 1(369):m1335.
- Derwand R, Scholz M. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win todays battle against COVID-19? Med Hypotheses. 2020May; 6:109815.
- *Gautret P, Lagier JC, Parola P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020Mar; 20(1):105949.
- Gautret P, Lagier JC, Parola P. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020Apr; 11:101663.
- Andreani J, Le Bideau M, Duflot I. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020Apr; 25:104228.
- Roche.com. 2020. Media Releases. [online] Available at: <https://www.roche.com/media/releases.htm> [Accessed2020Jul21].
- Isrctn.com. 2020. ISRCTN - ISRCTN50189673: A Randomised Trial Of Treatments To Prevent Death In Patients Hospitalised With COVID-19 (Coronavirus). [ online] Available at: <http://www.isrctn.com/ISRCTN50189673> [Accessed2020May15].
- Fang Q, Wang D. Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir. Biosaf Health. 2020Apr25;2(2):64–70.
- Sayad B, Sobhani M, Khodarahmi R. Sofosbuvir as repurposed antiviral drug against COVID-19: why were we convinced to evaluate the drug in a registered/approved clinical trial? Arch Med Res. 2020Aug1; 51(6):577–581.
- Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020;1432:9–10.
- Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020Apr27; 192(17):E450–3.
- Vouri SM, Thai TN, Winterstein AG. An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic. Res Social Adm Pharm. 2020 Apr30 [online]. Available at: <https://doi.org/10.1016/j.sapharm.2020.04.031>
- Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019‐nCoV infection. Clin Pharmacol Ther. 2020Apr4;108(2):242–247.
- Nature.com. 2020. Coronavirus Breakthrough: dexamethasone Is First Drug Shown To Save Lives. [online] Available at: <https://www.nature.com/articles/d41586-020-01824-5?utm_source=Nature+Briefing&utm_campaign=7fb7c54efa-briefing-dy-20200616&utm_medium=email&utm_term=0_c9dfd39373-7fb7c54efa-45156714> [Accessed2020Jun 20].
- Zhao Q, He Y. Challenges of convalescent plasma therapy on COVID-19. J Clin Virol. 2020Jun; 127:104358.
- *Shah B, Modi P, Sagar SR. In silico studies on therapeutic agents for COVID-19: drug repurposing approach. Life Sci. 2020Apr;9:117652.
- Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020Feb; 28:117477.
- Moreno AJ, Romero AR, Neochoritis C, et al. Gliptin repurposing for COVID-19. ChemRxiv. 2020 [online]. Available at: <https://doi.org/10.26434/chemrxiv.12110760.v1>.
- Kouznetsova VL, Huang D, Tsigelny IF. Potential COVID-19 protease inhibitors : repurposing FDA- approved drugs. 1–8. Available at: <https://chemrxiv.org/articles/Potential_COVID-19_Protease_Inhibitors_Repurposing_FDAapproved_Drugs/12093900> [Accessed 2020Aug21].
- Talluri S. Virtual Screening based prediction of potential drugs for COVID-19. Comb Chem High Throughput Screen. 2020Aug21 [online]. Availbale at: <https://doi.org/10.2174/1386207323666200814132149>.
- *Stebbing J, Phelan A, Griffin I. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020Apr1; 20(4):400–402.
- *Khodadadi E, Maroufi P, Khodadadi E, et al. Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19). Microb Pathog. 2020May;5:104241.
- Alakwaa FM. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data. Msystems. 2020Apr28;5(2). 10.1128/mSystems.00297-20
- Hawill B, Geraci J. Repurposing dupilumab may treat advanced COVID-19 patients with severe acute respiratory syndrome by mitigating cytokine storm [online]. Available at: <https://www.researchgate.net/profile/Bronnil_Hawill/publication/340084903_Repurposing_Dupilumab_May_Treat_Advanced_COVID-19_Pa-_tients_With_Severe_Acute_Respi-_ratory_Syndrome_By_Mitigating_Cytokine_Storm/links/5e7667924585157b9a51285e/Repurposing-Dupilumab-May-Treat-Advanced-COVID-19-Pa-tients-With-Severe-Acute-Respi-ratory-Syndrome-By-Mitigating-Cytokine-Storm.pdf> [Accessed 2020Aug21].
- Duarte RR, Jr DC C, Iñiguez LP. Repurposing FDA-Approved Drugs for COVID-19 Using a Data-Driven Approach. ChemRxiv. 2020 [online]. Available at: <https://doi.org/10.26434/chemrxiv.12148764.v1>.
- Bray M, Rayner C, Noël F, et al. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses. Antiviral Res. 2020Apr21;178:104805.
- Avchaciov K, Burmistrova O, Fedichev PO. AI for the repurposing of approved or investigational drugs against COVID-19. Res Gate. 2020;10. Available at: <https://www.researchgate.net/profile/Peter_Fedichev/publication/339998830_AI_for_the_repurposing_of_approved_or_investigational_drugs_against_COVID-19/links/5e71c42d299bf1571845af01/AI-for-the-repurposing-of-approved-or-investigational-drugs-against-COVID-19.pdf?_sg%5B0%5D=VhRsLOgYH807Dtm0OgE6OXbbwX7zmcDNMgQLWSjWTa2Q1jpSE0SdELoqZ1l8-hpvBFwQ0PFAmZz7MpA6SeGMZg.y0kcYUy_Pqapa7khCgaXMhHUw3AQSQs8Z6-mB1wC8_3Oo6FYVWuIOQnr6yhV8ZXwtSfQRsKrPWe1H6pqoK9d2Q&_sg%5B1%5D=IByAEqvNyMNmXkrazP-TZE2-o4WAnnGqXl6HVTCsSLCrvRnIpLY4EuSKGvu7E-d7ioGQ3HvjOi7-8iHjO04mfwBC7UUwUuvhfaneu8lKSTPx.y0kcYUy_Pqapa7khCgaXMhHUw3AQSQs8Z6-mB1wC8_3Oo6FYVWuIOQnr6yhV8ZXwtSfQRsKrPWe1H6pqoK9d2Q&_iepl=> [Accessed 2020Aug21].
- Wahedi HM, Ahmad S, Abbasi SW. Stilbene-based natural compounds as promising drug candidates against COVID-19. J Biomol Struct Dyn. 2020May; 7:0–1.
- Who.int. 2020. Clinical Management Of COVID-19. [online] Available at: <https://www.who.int/publications/i/item/clinical-management-of-covid-19> [Accessed2020Oct3].
- China National Health Comission. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment. 7 edition. 2020.;1–10. Available at: <http://kjfy.meetingchina.org/msite/news/show/cn/3337.html> [Accessed 2020Aug21].
- Simit.org. Italian Society of Infectious and Tropical Diseases handbook for care of people with COVID-19. Available at: <https://www.simit.org/IT/simit/sezioni-regionali.xhtml/sezione/112-lombardia/comunicazioni/1> [Accessed2020Sept30].
- U.S. Food and Drug Administration. 2020. Coronavirus Treatment Acceleration Program (CTAP). [online] Available at: <https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap> [Accessed2020Jul18].
- INSERM. Launch of a European clinical trial against COVID-19. 2020;19–21. Available at:<https://presse.inserm.fr/en/launch-of-a-european-clinical-trial-against-covid-19/38737/> [Accessed2020Jul18].
- U.S. Food and Drug Administration. 2020. U.S. Food And Drug Administration. [online] Available at: <https://www.fda.gov/> [Accessed2020Jul18].
- Government.ru. 2020. Ministry Of Health Of The Russian Federation - The Russian Government. [online] Available at: <http://government.ru/en/department/23/events/> [Accessed2020Jul18].
- Cdsco.gov.in. 2020. Home. [online] Available at: <https://cdsco.gov.in/opencms/opencms/en/Home/> [Accessed2020Jul18].
- Pmda.go.jp. 2020. PMDA’S Efforts To Combat COVID-19 | pharmaceuticals And Medical Devices Agency. [online] Available at: <https://www.pmda.go.jp/english/about-pmda/0002.html> [Accessed2020Sept30].
- Agenziafarmaco.gov.it. 2020. Welcome To The Italian Medicines Agency | AIFA Agenzia Italiana Del Farmaco. [online] Available at: <http://www.agenziafarmaco.govit/en> [Accessed 2020Jul18].